Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. MarketScreener Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : African Union drops AstraZeneca vaccine, which COVAX will supply

04/08/2021 | 05:26am EDT

* Africa CDC says decision not linked to clot fears

* Seeking more J&J shots while COVAX sources AstraZeneca

* Aiming not to compete with COVAX during supply crunch

NAIROBI, April 8 (Reuters) - The African Union's disease control body said on Thursday it had dropped plans to secure AstraZeneca COVID-19 vaccines for its members from the Serum Institute of India, the world's biggest vaccine supplier, amid global shortfalls of the shot.

AstraZeneca's $3 shot is by far the cheapest coronavirus vaccine launched so far, and the easiest to store and transport, making it well suited to developing countries.

On Wednesday, European and British medicine regulators said they had found possible links between the vaccine and extremely rare cases of brain blood clots, while emphatically reaffirming its importance in mass vaccination against COVID-19.

John Nkengasong, head of the Africa Centres for Disease Control and Prevention (Africa CDC), said the AU's decision had nothing to do with those findings, and reiterated his advice that the benefits of the vaccine outweighed the risks.

He said the main reason was to avoid duplicating COVAX's efforts by the World Health Organization-backed COVAX facility, which will continue to supply AstraZeneca to Africa.

He said the AU was focusing on the Johnson & Johnson vaccine, citing a deal announced last week to supply Africa with up to 400 million doses.

COVAX aims to deliver 600 million shots - most of them from AstraZeneca - to some 40 African countries this year, enough to vaccinate 20% of their populations.

Africa trails most other regions in COVID-19 vaccinations; fewer than 13 million doses have been administered on a continent of 1.3 billion people, according to the Africa CDC.

'NOT COMPETING'

The AU had wanted to secure up to 500 million additional AstraZeneca shots for its 55 member states, at $3 per shot.

However, last month India suspended its exports to meet rising domestic demand.

Nkengasong said the subsequent delays were complicating vaccination across Africa, noting that health systems had to know that second doses would be available in time for those who had received a first dose.

Matshidiso Moeti, who heads the WHO's Africa office, confirmed the two organisations wanted to ensure they were "not competing and stepping over each other looking for the same vaccines".

"I am very much assured that it is not to do with doubts about the safety and other considerations on the AstraZeneca vaccines. It's simply to recognise that there are challenges with the volumes that are available," she told a separate news briefing.

The single-shot J&J doses secured last week will not arrive until the third quarter, and Nkengasong said Africa would find it hard to bridge the gap in the meantime.

South Africa has cancelled orders of the AstraZeneca vaccine after finding it gave only minimal protection against mild-to-moderate infection caused by the country's dominant, highly infectious variant.

Russia and China are also offering vaccines, but there are questions about their cost and availability in large volumes.

The virus is confirmed to have killed 114,000 people across Africa, and infected 4.33 million. (Reporting by Maggie Fick; Writing by Katharine Houreld; Editing by Alex Richardson, Nick Macfie and Alison Williams)


© Reuters 2021
All news about ASTRAZENECA PLC
04/16ASTRAZENECA  : Quebec to deploy sound trucks in Montreal to announce mobile vacc..
AQ
04/16ASTRAZENECA  : Doctors say lowering age cutoff for AstraZeneca vaccine makes sen..
AQ
04/16Consumer Cos Climb On Reopening Optimism -- Consumer Roundup
DJ
04/16Health Care Up After Strong Start to Earnings Season -- Health Care Roundup
DJ
04/16Vaccine Manufacturing Issues Force Moderna to Cut Supplies to Canada, U.K.
DJ
04/16No Causal Link Found So Far Between J&J's Covid-19 Vaccine and Blood-Clot Cas..
DJ
04/16ASTRAZENECA  : German's IDT to make 10M AstraZeneca vaccine doses in 2021
AQ
04/16ASTRAZENECA  : Covid-19 - Lagos, Kano Lead As Nigeria Vaccinates Over 1m Persons
AQ
04/16MARKET CHATTER : Johnson & Johnson Reportedly Asked Other COVID-19 Vaccine Produ..
MT
04/16ASTRAZENECA  : Australia's Medicine Watchdog Links Woman's Death To AstraZeneca ..
MT
More news
Financials (USD)
Sales 2021 30 805 M - -
Net income 2021 5 064 M - -
Net Debt 2021 11 692 M - -
P/E ratio 2021 26,1x
Yield 2021 2,79%
Capitalization 134 B 134 B -
EV / Sales 2021 4,73x
EV / Sales 2022 4,09x
Nbr of Employees 76 100
Free-Float 95,8%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 129,60 $
Last Close Price 102,07 $
Spread / Highest target 62,6%
Spread / Average Target 27,0%
Spread / Lowest Target -7,74%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC0.76%133 897
JOHNSON & JOHNSON3.09%422 260
ROCHE HOLDING AG0.16%289 178
PFIZER INC.2.15%209 739
NOVARTIS AG-3.73%197 072
MERCK & CO., INC.-5.29%194 049